2023 World Conference on Lung Cancer (Posters)-EP11.02. Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC : A Multi-Center Prospective Study (Endouble)<b></b>

EP11.02. Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC : A Multi-Center Prospective Study (Endouble) - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference highlighted the efficacy and safety of combining Envafolimab and Endostar as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with PD-L1 positive expression. The combination of anti-angiogenesis therapy and immunotherapy has shown synergistic effects in NSCLC, resulting in longer response durations and improved survival rates. Envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, has already been approved for certain types of solid tumors in China. <br /><br />In this prospective, multi-center, single-arm study, 40 patients with advanced NSCLC and PD-L1 expression were enrolled. All patients received Envafolimab and Endostar every 3 weeks until disease progression, unacceptable toxicity, or patient refusal. The primary endpoint of the study was the response rate, determined using RECIST version 1.1 criteria, as well as safety and tolerability. Secondary endpoints included progression-free survival, overall survival, disease control rate, and duration of response. <br /><br />As of January 2023, 18 patients had been enrolled, with 13 patients undergoing efficacy evaluation. The majority of patients were male, with a median age of 67.8 years. 69% of patients were diagnosed at stage IV, and 77% had adenocarcinoma. The overall response rate was 62%, with 8 patients showing a partial response and 2 patients with stable disease. The median progression-free survival and median overall survival were not reached. The most common adverse events reported were elevated ALT, anemia, and hyponatremia, all of which were grade 1-2.<br /><br />Based on these results, the study concluded that the combination of Envafolimab and Endostar demonstrated promising efficacy and good tolerability in advanced NSCLC patients with PD-L1 expression. This combination therapy provides a new treatment option for these patients and further prospective studies are expected.

Asset Subtitle

Xiaodong Jiang

Meta Tag

Speaker Xiaodong Jiang

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

Envafolimab

Endostar

NSCLC

PD-L1 positive expression

combination therapy

response durations

survival rates

subcutaneous single-domain anti-PD-L1 antibody

progression-free survival

overall response rate